Jason A. Mouabbi, Assistant Professor at MD Anderson Cancer Center, shared a post by Sara Tolaney, Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, on X, adding:
”I totally agree! Showing OS benefit in the adjuvant setting of early stage HR+ HER2-ve is not easy at all! In fact I did not expect it! That’s why this is really impressive!”
Quoting Sara Tolaney‘s post:
”Very big news out today– adjuvant abemaciclib improves overall survival in high-risk ER+ breast cancer at ~7 years of follow up! Showing OS benefit in this setting is not easy and nice to see what an incredible impact adj cdk4/6i can have for our patients!”
More posts about Jason A. Mouabbi on OncoDaily.